P62-mediated mitophagy inducer (PMI) is a P62-mediated activator of mitophagy that functions independently of parkin recruitment or mitochondrial membrane potential (ΔΨm) collapse. It remains effective even in cells lacking a fully functional PINK1/Parkin pathway. PMI stabilizes Nrf2 and enhances p62 expression, thereby activating mitophagy.

P62-mediated mitophagy inducer (PMI) is a P62-mediated activator of mitophagy that functions independently of parkin recruitment or mitochondrial membrane potential (ΔΨm) collapse. It remains effective even in cells lacking a fully functional PINK1/Parkin pathway. PMI stabilizes Nrf2 and enhances p62 expression, thereby activating mitophagy.

Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.

BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression […]

P62-mediated mitophagy inducer (PMI) is a P62-mediated activator of mitophagy that functions independently of parkin recruitment or mitochondrial membrane potential (ΔΨm) collapse. It remains effective even in cells lacking a fully functional PINK1/Parkin pathway. PMI stabilizes Nrf2 and enhances p62 expression, thereby activating mitophagy.

BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression […]

BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression […]

BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression […]

PHI-101 is an orally active, potent third-generation inhibitor of FLT3 that overcomes resistance to multiple drug-resistant mutations. It has potential for research in relapsed or refractory acute myeloid leukemia (AML).

PHI-101 is an orally active, potent third-generation inhibitor of FLT3 that overcomes resistance to multiple drug-resistant mutations. It has potential for research in relapsed or refractory acute myeloid leukemia (AML).